Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Lymphomas

NCT06340737 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT06340737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06340737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Lymphomas
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Recruiting
Start date
March 29, 2024
Completion date
April 30, 2031
Enrollment
148 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, follicular lymphoma, hairy cell leukemia, large b-cell lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, waldenstrom macroglobulinemia